Jardiance

Chemical Nameempagliflozin
Dosage FormTablets (oral; 10 mg, 25 mg)
Drug ClassInhibitors
SystemEndocrine, Cardiovascular
CompanyBoehringer Ingelheim
Approval Year2014

Indication

  • An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
Last updated on 7/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Jardiance (empagliflozin) Prescribing Information.2022Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Document TitleYearSource
Impacts of sodium/glucose cotransporter-2 inhibitors on circulating uric acid concentrations: a systematic review and meta-analysis.2022Journal of Diabetes Research
Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis.2022Canadian Journal of Diabetes
Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials.2022Frontiers in Endocrinology
Comparative efficacy of five SGLT2i on cardiorenal events: a network meta-analysis based on ten CVOTS.2022American Journal of Cardiovascular Drugs
Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.2022Journal of Cardiovascular Pharmacology
Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials.2022European Heart Journal- Quality of Care and Clinical Outcomes
Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function.2022The Journal of Clinical Endocrinology & Metabolism
Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.2022European Journal of Preventative Cardiology
Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.2022Frontiers in Endocrinology
Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: a network meta-analysis based on randomized controlled trials.2022Journal of Clinical Pharmacy and Therapeutics
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.2021Heart Failure Reviews
High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: A meta-analysis of randomized clinical trials.2021Diabetes, Obesity and Metabolism
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: a systematic review and meta-analysis.2021IJC Heart and Vasculature
The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: a systematic review and meta-analysis.2021Diabetes, Obesity and Metabolism
Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: a systematic review. 2021Cureus
Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials.2021Heart Rhythm
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. 2021Medicine
Microvascular benefits of new antidiabetic agents: a systematic review and network meta-analysis of kidney outcomes.2021Journal of Clinical Endocrinology & Metabolism
Empagliflozin in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. 2021Frontiers in Cardiovascular Medicine
Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. 2021Diabetes Research and Clinical Practice
Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. 2021Cardiovascular Drugs and Therapy
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.2021Diabetes, Obesity and Metabolism
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. 2020Annals of Internal Medicine
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. 2020The Lancet Diabetes and Endocrinology
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. 2020The Lancet Diabetes and Endocrinology
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: a systematic review and meta-analysis.2020PLoS One
Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis.2020Medical Sciences
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: a systematic review and meta-analysis.2020Medicine
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis.2019PLoS Medicine
Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: a meta-analysis of randomized controlled trials. 2019Diabetes Research and Clinical Practice
Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: systematic literature review and indirect comparisons.2018Diabetes Therapy
Efficacy and safety of empagliflozin for type 2 diabetes mellitus: meta-analysis of randomized controlled trials.2018Medicine
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: a systematic review and meta-analysis. 2018Diabetes Obesity and Metabolism
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: a systematic review with an indirect comparison meta-analysis.2018Saudi Journal of Biological Sciences
Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials.2018CMAJ Open
Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. 2018Diabetes and Metabolism
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.2017Diabetologia
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. 2017Diabetes Research and Clinical Practice
Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.2017Diabetes Obesity and Metabolism